Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog



NicOx’s nitro-derivative of naproxen, HCT 3012, shown to be effective in a model of myocardial infarction

11 May 04

DailyUpdates 11th May: A number of clinical studies including the VIGOR trial have suggested that the NSAID naproxen may reduce the incidence of myocardial infarction. However the gastrointestinal side-effects of naproxen and its ability to exacerbate hypertension preclude its use in at-risk individuals. Upcoming data about to be published in the journal JPET demonstrate the efficacy of the safer and anti-hypertensive nitro-derivative of naproxen, HCT 3012, in a model of myocardial infarction.

Results from the PACES trials provides further good news for Pfizer’s Celebrex (celecoxib)

10 May 04

DailyUpdates 10th May: Last week European regulators affirmed the safety of Celebrex; good news for Pfizer continues with the emergence of data from the PACES trials reporting that, compared to acetaminophen, Celebrex is both preferred by patients and is of greater efficacy.

Signal Detection throughout the Product Life Cycle

07 May 04

Learn innovative ways to analyze data derived from signals in clinical development as well as post-maketing surveillance.
Jennifer McGinnis

Emerging Drug Discovery Targets 6th May

06 May 04

This edition of Emerging Drug Discovery Targets features MBD2 inhibitors as a selective strategy for reducing tumor growth; NicOx's NO-ASA cancer candidate, NCX 4040, MIF as a target for atherogenesis; expanding indications for COX-2 inhibitors; and a dual MMP and TACE inhibitor as a treatment of rheumatoid arthritis. This edition also sees a new section "TherapyUpdate" which this month focuses on Osteoporosis. As usual we also provide updates on industrial advances and licensing opportunities a

Who's Going to Develop our Next Medicines?

06 May 04

Join Dr Philip Wright, Director of Science at the ABPI live online to find out.
Dr Philip Wright

Gabapentin as a first line treatment of spinal cord injury-related neuropathic pain

05 May 04

DailyUpdates 5th May: As the battle lines are drawn up between gabapentin and its generic equivalents, research published by Turkish researchers suggests that the first-line use of these therapeutics in the treatment of neuropathic pain associated with spinal cord injury will represent one battle in the war between Pfizer and its competitors.

New data reveals that the calcium channel blocker ethosuximide is an effective treatment of cancer pain

29 Apr 04

DailyUpdates 29th April: Cancer pain affects over 3 million people in the US alone. The treatment of this condition, whether it is due to bone metastasis or a result of the use of cytotoxic therapies is challenging. Researchers from McGill University have now demonstrated that ethosuximide, an anti-epileptic and relatively selective T-type calcium channel blocker, is highly effective in reversing neuropathic pain caused by the commonly employed cytotoxics paclitaxel or vincristine. This contr

The Pharmaceutical Industry needs Pharmacists – How can we move them from behind the counter?

26 Apr 04

There are certainly a variety of challenges available in industry but it often means moving to different parts of the company and uprooting to get that variety.
Mike Breese and Jeff Webb

Merckle demonstrate superior safety of Licofelone the first dual COX/LOX inhibitor: Opportunities for improved osteoarthritis treatment

22 Apr 04

DailyUpdates 22nd April: Phase III studies have previously shown Merkle’s first in the class COX/LOX inhibitor, Licofelone, to be equally effective to standard treatments of osteoarthritis. Moreover, gastrointestinal adverse events tended to be less frequent in patients treated with licofelone as compared to naproxen. In this month’s edition of the American Journal of Gastroenterology new data is published showing clear cut advantages of licofelone arising from the dramatic reduction in incide

HU-320 identified as a novel synthetic cannabinoid with therapeutic activity in an experiment model of rheumatoid arthritis

20 Apr 04

DailyUpdates 20th April: An estimated 5 million individuals suffer from rheumatoid arthritis in the Western world. CB1 cannabinoid receptor ligands are in development as candidate treatments of this disease due to their analgesic properties. Now researchers from the Hebrew University and the Kennedy Institute of Rheumatology in London have demonstrated the anti-inflammatory, disease modifying efficacy of the non-psychoactive cannabinoid, HU-320 in a model of rheumatoid arthritis.

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.